Paul Swerdlow

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

American Journal of Hematology · 2010 · 400 citations

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

British Journal of Haematology · 2007 · 223 citations